Appointment of Mr. Dalavath Amar Singh as Additional Director ( Executive Category) of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Decipher Labs' board, at its November 13, 2025 meeting, approved the appointment of Mr. Dalavath Amar Singh (DIN: 02206249) as Additional Director in the Executive Category for a 2-year term at Rs. 6 lakh per annum, subject to shareholder approval. Mr. Singh has operational experience in the pharmaceutical industry covering plant operations, team coordination, and production. The board also approved unaudited Q2 and H1 FY26 results. On a standalone basis, Q2 FY26 revenue was Rs. 8.80 lakhs with a loss of Rs. 11.55 lakhs; H1 FY26 revenue rose to Rs. 93.45 lakhs (vs Rs. 36.72 lakhs in H1 FY25) with a narrower loss of Rs. 5.96 lakhs. On a consolidated basis, Q2 FY26 revenue fell to Rs. 431.37 lakhs (vs Rs. 586.67 lakhs a year ago) and H1 FY26 loss widened sharply to Rs. 340.66 lakhs (vs Rs. 38.14 lakhs loss in H1 FY25), largely driven by subsidiaries in the USA and Bahrain.
The appointment adds pharmaceutical operations know-how to the board, which is a positive for a pharma-focused company. However, weakening consolidated revenues and a much wider H1 loss at the group level may weigh on investor sentiment despite the improved standalone numbers.